NSRX ▲ +6.8% - Nasus Pharma Ltd. $NSRX - Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis Nasus Pharma rose 6.8% after announcing FDA clearance to begin a clinical study of its NS002 candidate for anaphylaxis treatment. The regulatory green light to advance the drug program appears to have driven investor optimism in the stock. 14-SEP-2026 08:01 AM ET